



CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

June 12, 2025 11:00 AM EDT

LA JOLLA, Calif., June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy.



Details for the oral presentations to be presented during the symposium are as follows:

Presentation Title: Overview of Calcium Release-Activated Calcium (CRAC) Channels

Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica

Date and Time: Tuesday, June 24, 1:45-2:00 p.m. CEST

Presentation Title: The Role of IL-17 in the Pathophysiology of AKI

Presenter: Javier Neyra, M.D., Associate Professor of Medicine and Associate Director of the Nephrology Research & Training Center at University of Alabama at Birmingham

Date and Time: Tuesday, June 24, 2:00-2:20 p.m. CEST

Presentation Title: KOURAGE (NCT06374797)

Presenter: Lakshmir Chawla, M.D., Clinical Professor of Medicine at University of California San Diego, Chief Medical Officer at ExThera Medical, and Chair of the KOURAGE Steering Committee

Date and Time: Tuesday, June 24, 2:20-2:35 p.m. CEST

Webcasts of the presentations will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at <https://ir.calcimedita.com/news-events/medical-events-publications>.

About CalciMedica

CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – [NCT04681066](#)) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – [NCT04345614](#)) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – [NCT06374797](#)) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visit www.calcimedita.com.

Contact Information

Argot Partners

calcimedita@argotpartners.com

(212) 600-1902

View original content to download multimedia: <https://www.prnewswire.com/news-releases/calcimedita-announces-upcoming-symposium-at-the-43rd-vicenza-course-aki-crrt-ebpt-and-critical-care-nephrology-meeting-302479338.html>

SOURCE CalciMedica, Inc.